Tonix publishes Day 20 steady-state PK study of TONMYA in clinical journal

• Tonix Pharmaceuticals disclosed peer-reviewed publication of a steady-state pharmacokinetic study of TONMYA (cyclobenzaprine HCl sublingual tablets) following 20 days of daily dosing.
• Results were presented as already published in Clinical Pharmacology in Drug Development.
• Study outcome showed TONMYA produced lower overall drug exposure than an oral extended-release cyclobenzaprine comparator while delivering faster uptake consistent with bedtime, long-term use in fibromyalgia.
• Safety profile over 20 days was generally tolerable with no serious adverse events or discontinuations, supporting ongoing commercialization following U.S. launch in November 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604150700PRIMZONEFULLFEED9689936) on April 15, 2026, and is solely responsible for the information contained therein.